论文部分内容阅读
异搏停(verapamil)为一种钙通道阻断剂。最近报道它能降低负鼠食管下端括约肌压力(LESP)。但至今尚未见有异搏停对人类LESP的影响的研究。作者研究了异搏停对正常人静态LESP的影响,并探讨用异搏停治疗食管失弛缓症的可能性。方法 8名正常男性志愿者,平均年龄29岁,无食管疾病症状。7例食管失弛缓症包括女4、男3例,平均年龄40岁。诊断标准如下:①有吞咽困难症状;②上消化道X线检查示食管扩张,食管远端呈平滑地逐渐变细,蠕动停止;③内窥镜除外器质性狭窄和恶性肿瘤;④食管压力计证实有下端括约肌松弛不全和食管体部全段蠕动停止。压力测定系通过水灌注式三
Verapamil is a calcium channel blocker. It has recently been reported that it reduces esophageal lower sphincter pressure (LESP). However, no study on the impact of verapamil on human LESP has been reported so far. The authors studied the effects of verapamil on normal human LESP and discussed the possibility of verapamil for the treatment of esophageal achalasia. Methods Eight normal male volunteers, mean age 29 years, had no symptoms of esophageal disease. 7 cases of esophageal achalasia, including female 4, 3 males, mean age 40 years. Diagnostic criteria are as follows: ① symptoms of dysphagia; ② upper gastrointestinal X-ray showed esophageal dilatation, esophageal distal smooth and tapered, cessation stopped; ③ endoscopic strictures and malignant tumors; ④ esophageal pressure It is confirmed that the lower end of the sphincter relaxation and full stop the esophageal body. Pressure measurement through the water infusion type three